Dr. Shustov's research is focused on development of novel therapeutic strategies and implementation of targeted biologic agents into treatment paradigms of peripheral T-cell lymphomas and cutaneous T-cell lymphomas. In addition, he dedicates a lot of his activities in developing national and international collaborations to study these rare lymphoid tumors.
Active Clinical Trials:
A Phase 1, Dose-Finding Study of Folotyn ® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)A Phase 2 study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for the treatment of T-cell Non-Hodgkin LymphomaA Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn ® (Pralatrexate Injection) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
A phase 1 dose finding study of brentuximab vedotin in combination with ceritinib in patients with newly diagnosed ALK-positive Anaplastic Large Cell Lymphoma.
A phase 2 clinical trial of romidepsin and oral azacitidin in patients with relapsed and refractory peripheral T-cell lymphomas.
Seattle Cancer Care AllianceMailbox G3-200825 Eastlake Ave., EastSeattle, WA 98109-1024
Development of novel therapeutic strategies and implementation of targeted biologic agents into treatment paradigms of peripheral T-cell lymphomas and cutaneous T-cell lymphomas
Non-Hodgkin and Hodgkin lymphomas, T-cell lymphomas, cutaneous T-cell lymphomas, and acute lymphocytic leukemia